CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Breckpoint

Breckpoint is dedicated to helping brokers and employers build alternative risk solutions outside of the traditional insurance providers. For employers seeking an alternative to fully-insured group benefit plans or self-insured groups for workers compensation, Breckpoint empowers groups to take advantage of the transparency, control, and underwriting profits generated by high performing self-funded plans. - Self funded benefit administration plans - Self-insured group administration for workers compensation - Captive Management - Risk Management services We believe in Leading Together. This is the essence of Breckpoint. We are here with you through every step of this benefit journey. Your Breckpoint team provides the stellar service you deserve and we look forward to helping you manage your alternative risk programs.

MedicareSchool.com

With so much conflicting and confusing information surrounding Medicare, its easy to feel unsure about how to choose the best plan(s). At MedicareSchool.com, we empower you with the knowledge and guidance you need to get the best Medicare plans and live retirement worry-free.

Proctor Loan Protector

Our lender-placed insurance, blanket insurance, and specialty insurance programs provide comprehensive coverage to financial institutions, government entities, property investors, and property & casualty agencies. Proctor Loan Protectors service solutions are powered by superior customer service, proprietary innovations, technology, and an experienced team. We perform insurance tracking, which includes policy procurement, mail processing, disbursement facilitation, and an award-winning borrower call center.

DuBois Chemicals, Inc.

DuBois Chemicals, Inc. is a prominent specialty chemical supplier with a history that dates back to 1920. Based in Hamilton, Ohio, the company is dedicated to providing innovative and economical solutions across various industries. DuBois focuses on delivering custom chemical solutions that enhance efficiency and reliability in industrial processes, emphasizing customer satisfaction and sustainability. The company offers a diverse product portfolio that includes cleaning and process solutions for general manufacturing, specialized chemicals for the pulp and paper industry, transportation cleaning solutions, and water treatment chemicals. With a significant facility in Cincinnati, Ohio, DuBois employs over 150 staff members, including scientists and customer service representatives, and has a strong sales team of over 400 representatives serving customers throughout North America. DuBois Chemicals demonstrates financial strength with revenues ranging from $100 million to $1 billion, allowing for continued investment in research and development.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.